source
- FDA probes cancer risk from Zolgensma gene therapy after post-marketing tumor reportsThe FDA has issued a safety communication indicating it is investigating reports of malignancies in patients treated with Zolgensma, the adeno‑associated virus gene therapy for spinal muscular atro…
- Novartis reports nine cancer cases in patients treated with Zolgensma gene therapyNovartis disclosed that nine individuals with spinal muscular atrophy who received its gene therapy Zolgensma later developed tumors. Two of the cases showed evidence that the adeno-associated vir…